Flutamide is indicated for the treatment of advanced prostatic carcinoma in which suppression of testosterone effects is indicated. Flutamide may be used in combination with an LHRH agonist, both on commencement of treatment or as an adjunctive therapy in patients already receiving an LHRH agonist. Flutamide may also be used in surgically castrated patients.
For this indication, competent medicine agencies globally authorize below treatments:
750 - 750 mg
From 250 To 250 mg 3 time(s) per day every day
250 mg three times daily at 8 hour intervals. When flutamide is used as initial treatment with an LHRH agonist, a reduction in severity of the flare reaction may be achieved if treatment with flutamide is initiated before the LHRH agonist. Consequently, it is recommended that treatment with flutamide should commence simultaneously or at least 24 or more hours before the LHRH agonist.
The administration of flutamide should begin 8 weeks prior to radiotherapy and continue for its duration, or for 12 weeks pre-prostatectomy.
In patients with impaired liver function, long-term treatment with flutamide should only be initiated after careful assessment of the individual benefits and risks.
Flutamide should be administered with caution in patients with impaired renal function.
It should be taken preferably after food.